STOCKHOLM, July 16, 2019 /PRNewswire/ -- Sobi™ has
established the Sobi Scientific Innovation Awards, with a focus on
the future of haemophilia care, to recognise innovation and
scientific excellence in haemophilia research.
Entries will be assessed by an Adjudication Committee of
independent, international haemophilia experts, according to
scientific credit and contribution to haemophilia, overall concept
novelty, as well as the anticipated ability of the research to help
liberate life for people with haemophilia.
Armin Reininger, Head of Medical
and Scientific Affairs at Sobi, says the aim is to focus on
research that reflects a meaningful difference for patients.
"We are proud to support Investigator-Sponsored Studies because
the research conducted by the community adds substantially to an
increased understanding of pre-clinical and clinical value of
haemophilia treatment," Armin says. "With these inaugural awards,
we hope to encourage existing and up-and-coming researchers in this
field to share new insights and strong results that that can
elevate our understanding of haemophilia and raise the standard of
care , thereby helping patients live a life beyond
haemophilia."
The 2019 Sobi Scientific Innovation Awards will be presented in
two categories: Clinical and Pre-clinical. Submissions are welcome
from healthcare professionals working in the field of haemophilia,
who have an ongoing Sobi Investigator-Sponsored Study (ISS), or who
are a recipient of a Sobi medical grant. All nominated awards
applicants will be invited to attend the Sobi Scientific Update
Meeting in Amsterdam 17-18 October 2019 to have an opportunity to
showcase their submitted research.
The Awards Adjudication Committee will be looking for:
- Excellence in study design
- Excellence in study conduct, including methodology, data
collection, processing and evaluation
- Impactful results/conclusions that advance basic science
or will contribute to improving outcomes/liberating the life of
people with haemophilia
- High-quality presentation of baseline information,
hypothesis, study data, interpretations or insights
Submissions can be entered until 30
August 2019 via the online submission website.
About Sobi™
At Sobi, we are transforming the lives of people affected by
rare diseases. As a specialised international biopharmaceutical
company, we provide sustainable access to innovative therapies in
the areas of haematology, immunology and specialty care. We bring
something rare to rare diseases – a belief in the strength of
focus, the power of agility and the potential of the people we are
dedicated to serving. The hard work and dedication of our
approximately 1050 employees around the globe has been instrumental
in our success across Europe,
North America, the Middle East, Russia and North
Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi's share (STO:SOBI)
is listed on Nasdaq Stockholm. You can find more information about
Sobi at http://www.sobi.com/
For more information please contact
Paula Treutiger, Head
of Communication & Investor Relations
|
|
0733-666-599
|
|
paula.treutiger@sobi.com
|
|
|
|
Linda Holmström,
Corporate Communication & Investor Relations
|
|
0708-734-095
|
|
linda.holmstrom@sobi.com
|
|
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-invites-entries-to-first-sobi-scientific-innovation-awards,c2863794
The following files are available for download:
https://mb.cision.com/Main/14266/2863794/1077908.pdf
|
Sobi Scientific
Innovation Awards press release
|
View original
content:http://www.prnewswire.com/news-releases/sobi-invites-entries-to-first-sobi-scientific-innovation-awards-300885435.html
SOURCE Swedish Orphan Biovitrum AB